A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
Completed · Phase 1 · NCT06433505
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- Celgene
- Tested
- BMS-986365 (drug), [14C] BMS-986365 (drug), [14C] BMS-986409 + BMS-986410 (drug), [14C] BMS-986410 + BMS-986409 (drug)
- Dates
- Started 2024-05-30; completion 2025-02-28
- Results posted
- Not yet
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
From ClinicalTrials.gov, last updated 2025-03-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1.1M in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research $1.1M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.